Much improved outcome with gabapentin-divalproex combination in adults with bipolar disorders and developmental disabilities.
Hellings
Jessica A
JA
D000293:Adolescent; D000328:Adult; D000588:Amines / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D002658:Developmental Disabilities / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D004338:Drug Combinations; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008094:Lithium / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D000588:Amines; D018692:Antimanic Agents; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D008094:Lithium